Shiseido Co., Ltd. (TOKYO:4911) has long focused its research on skin immunity as an important means of maintaining skin's health, and protecting it from external and internal stressors that can lead to dermatologic problems. Through this research, Shiseido discovered that one function of skin immunity, the self-protection function that sedates the stimuli response factors of Langerhans cells, is important to maintaining skin homeostasis and that this function declines with age.
Shiseido has developed a multiple component that effectively combines three ingredients, including β-glucan, to target the Langerhans cells and help recover their self-protection function. Shiseido has applied for a patent for this technology in nine countries, including Japan. Furthermore, with a prototype serum incorporating this multiple component, Shiseido proved for the first time that the skin's self-protection function can be recovered.
Shiseido is currently planning to engage in R&D for the launch of a skincare product applying these research results.
Shiseido has been researching skin immunity for more than 20 years. This includes collaborative research with the Massachusetts General Hospital/Harvard Cutaneous Biology Research Center in Boston, Massachusetts, an internationally recognized dermatological research institute.